PharmD Signal™: Clinical Pharmacy Literature, Analyzed | PharmD Signal

214 analyses · 10 new this week · updated Aug 20

Welcome to PharmD Signal™

Peer-reviewed clinical pharmacy literature, analyzed for practicing pharmacists. Set your topics to personalize.

⭐ Featured Analysis

Cardiology / Anticoagulation Practice-changing Grade: High

Aspirin Monotherapy Noninferior to Rivaroxaban Bridge After Arthroplasty

Published in: N Engl J Med · Jul 12, 2026

Aspirin matches rivaroxaban's efficacy in preventing post-surgical blood clots.

Read Full Analysis →

Newest Analyses

Pharmacokinetics / TDMTDM Not Yet Justified for Non-Anti-TNF IBD TherapiesPublished in: Frontiers in Gastroenterology (Lausanne, Switzerland)

Medication SafetyPrescribing Drives Most Errors; Pharmacists Intercept MajorityPublished in: Saudi Medical Journal

Endocrinology / Diabetes / ObesityDeintensification Lags Despite Overtreatment in Older Diabetes PatientsPublished in: JAMA Internal Medicine

Cardiology / AnticoagulationTirzepatide Beats Dulaglutide on Cardiorenal Outcomes in Real-World HFpEFPublished in: Clinical Cardiology

💊 Clinical Pearl of the Week

Tirzepatide Beats Dulaglutide on Cardiorenal Outcomes in Real-World HFpEF Cardiology / Anticoagulation

Anchor incretin decisions in HFpEF to randomized data: the SUMMIT trial supports tirzepatide for obesity-related HFpEF but showed a numerically higher mortality HR of 1.25, opposite to this analysis.

⚡ Practice-changing

⚠️FDA Safety Alerts2 Recent

Fresenius Kabi Recalls One Lot of Tyenne (tocilizumab-aazg) for Glass Particles

Medication Safety · Aug 11, 2026

Tyenna Injection Recalled for Glass Contamination

Medication Safety · Aug 11, 2026

Most-read this week

1EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine RecommendationsRheumatology / Immunology

2Finerenone Cuts Heart Failure Events in HFmrEF and HFpEFCardiology / Anticoagulation

3SGLT2 Inhibitor Uptake Rises but Misses Highest-Risk HFrEF PatientsCardiology / Anticoagulation